IGF-1R and mTOR Blockade: Novel Resistance Mechanisms and Synergistic Drug Combinations for Ewing Sarcoma

An Oral Formulation of YK-4-279: Preclinical Efficacy and Acquired Resistance Patterns in Ewing Sarcoma

(2015) S.-E. Lamhamedi-Cherradi et al.   MOLECULAR CANCER THERAPEUTICS

Flow perfusion effects on three-dimensional culture and drug sensitivity of Ewing sarcoma

(2015) Marco Santoro et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Epigenome Mapping Reveals Distinct Modes of Gene Regulation and Widespread Enhancer Reprogramming by the Oncogenic Fusion Protein EWS-FLI1

(2015) Eleni M. Tomazou et al.   Cell Reports

Germline PTPRD Mutations in Ewing Sarcoma: Biologic and Clinical Implications

(2015) Yunyun Jiang et al.   Oncotarget

EWS-FLI1 Utilizes Divergent Chromatin Remodeling Mechanisms to Directly Activate or Repress Enhancer Elements in Ewing Sarcoma

(2014) Nicolò Riggi et al.   CANCER CELL

MEDI-573, Alone or in Combination with Mammalian Target of Rapamycin Inhibitors, Targets the Insulin-like Growth Factor Pathway in Sarcomas

(2014) H. Zhong et al.   MOLECULAR CANCER THERAPEUTICS

Phase II study of cixutumumab in combination with temsirolimus in pediatric patients and young adults with recurrent or refractory sarcoma: A report from the children's oncology group

(2014) Lars M. Wagner et al.   PEDIATRIC BLOOD & CANCER

Combating Resistance to Anti-IGFR Antibody by Targeting the Integrin β 3-Src Pathway

(2013) Dong Hoon Shin et al.   JNCI-Journal of the National Cancer Institute

Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial

(2013) Gary K Schwartz et al.   LANCET ONCOLOGY

Downregulation of IGFBP2 is associated with resistance to IGF1R therapy in rhabdomyosarcoma

(2013) Z Kang et al.   ONCOGENE

Modeling Ewing sarcoma tumors in vitro with 3D scaffolds

(2013) E. L. S. Fong et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Targeting the EWSR1-FLI1 Oncogene-Induced Protein Kinase PKC-  Abolishes Ewing Sarcoma Growth

(2012) D. Surdez et al.   CANCER RESEARCH

Insulin Growth Factor-Receptor (IGF-1R) Antibody Cixutumumab Combined with the mTOR Inhibitor Temsirolimus in Patients with Refractory Ewing's Sarcoma Family Tumors

(2012) A. Naing et al.   CLINICAL CANCER RESEARCH

Identification of Common and Distinctive Mechanisms of Resistance to Different Anti-IGF-IR Agents in Ewing's Sarcoma

(2012) Cecilia Garofalo et al.   MOLECULAR ENDOCRINOLOGY

Dual IGF-I/II-Neutralizing Antibody MEDI-573 Potently Inhibits IGF Signaling and Tumor Growth

(2011) J. Gao et al.   CANCER RESEARCH

Expression of insulin-like growth factor system components in Ewing’s sarcoma and their association with survival

(2011) Katia Scotlandi et al.   EUROPEAN JOURNAL OF CANCER

R1507, a Monoclonal Antibody to the Insulin-Like Growth Factor 1 Receptor, in Patients With Recurrent or Refractory Ewing Sarcoma Family of Tumors: Results of a Phase II Sarcoma Alliance for Research Through Collaboration Study

(2011) Alberto S. Pappo et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy of Ganitumab (AMG 479), Alone and in Combination with Rapamycin, in Ewing's and Osteogenic Sarcoma Models

(2011) P. J. Beltran et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Efficacy of and resistance to anti-IGF-1R therapies in Ewing's sarcoma is dependent on insulin receptor signaling

(2011) C Garofalo et al.   ONCOGENE

Combination testing (Stage 2) of the Anti-IGF-1 receptor antibody IMC-A12 with rapamycin by the pediatric preclinical testing program

(2011) E. Anders Kolb et al.   PEDIATRIC BLOOD & CANCER

Targeted Morphoproteomic Profiling of Ewing's Sarcoma Treated with Insulin-Like Growth Factor 1 Receptor (IGF1R) Inhibitors: Response/Resistance Signatures

(2011) Vivek Subbiah et al.   PLoS One

Overcoming mTOR inhibition-induced paradoxical activation of survival signaling pathways enhances mTOR inhibitors’ anticancer efficacy

(2010) Xuerong Wang et al.   CANCER BIOLOGY & THERAPY

A Phase I Study of Weekly R1507, A Human Monoclonal Antibody Insulin-like Growth Factor-I Receptor Antagonist, in Patients with Advanced Solid Tumors

(2010) R. Kurzrock et al.   CLINICAL CANCER RESEARCH

Targeting Insulin-Like Growth Factor Signaling: Rational Combination Strategies

(2010) D. Olmos et al.   MOLECULAR CANCER THERAPEUTICS

Mnk earmarks eIF4E for cancer therapy

(2010) N. Hay   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The Insulin-like Growth Factor-1 Receptor-Targeting Antibody, CP-751,871, Suppresses Tumor-Derived VEGF and Synergizes with Rapamycin in Models of Childhood Sarcoma

(2009) R. T. Kurmasheva et al.   CANCER RESEARCH

Phase I, Pharmacokinetic, and Pharmacodynamic Study of AMG 479, a Fully Human Monoclonal Antibody to Insulin-Like Growth Factor Receptor 1

(2009) Anthony W. Tolcher et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeting insulin-like growth factor type 1 receptor in cancer therapy

(2009) Francesco Atzori et al.   Targeted Oncology

Development of IGF-IR inhibitors in pediatric sarcomas

(2009) E. Anders Kolb et al.   Current Oncology Reports

Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program

(2008) E. Anders Kolb et al.   PEDIATRIC BLOOD & CANCER